- The FDA has granted 510(k) clearance for Apyx Medical Corporation’s (NASDAQ:APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance of lax skin in the neck and submental region.
- Renuvion is a proprietary helium plasma and radiofrequency technology.
- Related: Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin.
- This clearance offers a new option for physicians and patients to improve loose skin on the neck and submental region.
- With this clearance, Renuvion is the only product that is FDA-cleared to improve the appearance of loose skin on the neck and chin.
- Renuvion provides a minimally-invasive and cost-effective option with minimal downtime. The results reveal a more contoured and smoother neck and jawline.
- Price Action: APYX shares are up 9.20% at $8.31 during the market session on the last check Monday
Why Ocugen Stock Is Climbing Today
Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
